Sam Barker Biography and Net Worth



Dr. Barker has served as a director of the Company since September 2014. Dr. Barker has more than 40 years of experience in senior executive positions in the pharmaceutical industry where he played a significant role in the commercialization and success of several important pharmaceuticals including Taxol®, Capoten®, Glucophage® and Pravachol®. In 2001, Dr. Barker co-founded Clearview Projects, Inc., a provider of partnering and transaction services to biopharmaceutical companies, where he worked until September 2010, having served as its President and Chief Executive Officer from 2003 to 2004. Dr. Barker served in a series of leadership positions at Bristol-Myers Squibb Company until his retirement in 1999. His positions at Bristol-Myers Squibb included service as Executive Vice President, Worldwide Franchise Management and Strategy during 1998; President, United States Pharmaceuticals from 1992 to 1998; and President, Bristol-Myers Squibb Intercontinental Commercial Operations from 1989 to 1991. Prior to 1989, Dr. Barker held executive positions in research and development, manufacturing, business development and operations planning at Squibb Pharmaceuticals. Dr. Barker has served as a director of Lexicon Pharmaceuticals, Inc. since 2001 and as Chairman from 2005 to 2012. Dr. Barker also served as a director of Cadence Pharmaceuticals, Inc. from 2006 to 2014 and AtheroGenics, Inc. from 2005 to 2009. Dr. Barker received his B.S. from Henderson State College, his M.S. from the University of Arkansas and his Ph.D. from Purdue University.

What is Sam L. Barker's net worth?

The estimated net worth of Sam L. Barker is at least $14,829.00 as of August 2nd, 2019. Dr. Barker owns 40,187 shares of Cyclacel Pharmaceuticals stock worth more than $14,829 as of November 18th. This net worth estimate does not reflect any other assets that Dr. Barker may own. Learn More about Sam L. Barker's net worth.

How do I contact Sam L. Barker?

The corporate mailing address for Dr. Barker and other Cyclacel Pharmaceuticals executives is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. Cyclacel Pharmaceuticals can also be reached via phone at (908) 517-7330 and via email at [email protected]. Learn More on Sam L. Barker's contact information.

Has Sam L. Barker been buying or selling shares of Cyclacel Pharmaceuticals?

Sam L. Barker has not been actively trading shares of Cyclacel Pharmaceuticals in the last ninety days. Most recently, Sam L. Barker sold 0 shares of the business's stock in a transaction on Tuesday, November 30th. The shares were sold at an average price of $53.55, for a transaction totalling $0.00. Learn More on Sam L. Barker's trading history.

Who are Cyclacel Pharmaceuticals' active insiders?

Cyclacel Pharmaceuticals' insider roster includes Sam Barker (Director), and Spiro Rombotis (CEO). Learn More on Cyclacel Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Cyclacel Pharmaceuticals?

In the last year, Cyclacel Pharmaceuticals insiders bought shares 2 times. They purchased a total of 7,956 shares worth more than $26,334.36. The most recent insider tranaction occured on December, 21st when insider Paul Mcbarron bought 1,886 shares worth more than $6,242.66. Insiders at Cyclacel Pharmaceuticals own 8.0% of the company. Learn More about insider trades at Cyclacel Pharmaceuticals.

Information on this page was last updated on 12/21/2023.

Sam L. Barker Insider Trading History at Cyclacel Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2021Sell0$53.55$0.00View SEC Filing Icon  
11/20/2014Buy206$45.00$9,270.00View SEC Filing Icon  
See Full Table

Sam L. Barker Buying and Selling Activity at Cyclacel Pharmaceuticals

This chart shows Sam L Barker's buying and selling at Cyclacel Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cyclacel Pharmaceuticals Company Overview

Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
Read More

Today's Range

Now: $0.37
Low: $0.36
High: $0.37

50 Day Range

MA: $0.85
Low: $0.37
High: $1.43

2 Week Range

Now: $0.37
Low: $0.35
High: $6.00

Volume

75,125 shs

Average Volume

709,364 shs

Market Capitalization

$793,350.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56